INSIGHTS ON CELL & GENE THERAPY LOGISTICS

• Addressing The Acetonitrile Supply By Implementing Strategies

  Rising acetonitrile demand threatens supply chains; recovery and reuse methods using evaporation and crystallization produce high‑purity solvent, reducing costs, waste, and reliance on fresh supply.

• Accelerated Delivery Of Manufacturing Capacity

  When demand spikes unexpectedly, standardized facility design and aligned equipment strategies can dramatically shorten expansion timelines. See how to reduce uncertainty across procurement.

• Reducing Inventory Errors In Clinical Trials

  Can a digital double-check save your trial from data errors? How does verifying shipments at receipt slash inventory mistakes? Learn to protect protocol integrity and patient safety.

• 9 Logistics And Distribution Recommendations For CGTs

  Cell and gene therapy commercialization requires tailored logistics strategies. Explore nine recommendations covering site readiness, reimbursement gaps, packaging, testing, and coordination.

• Inside March Biosciences' CD5-Targeting CAR-T Approach

  Fratricide is one of the key reasons T-cell therapies targeting T-cell malignancies have faltered. March's approach aims to solve that with its MB-105 candidate.

• Accelerate Your Trials With An End‑To‑End Supply Chain Model

  An end-to-end supply chain model helps clinical trials move faster while maintaining visibility, control, and risk management across complex, temperature‑sensitive, and global operations.

• From Bench To Breakthrough: How Custom Kitting Fuels Precision Trials

  Reduce trial variability and ensure protocol compliance with standardized custom kitting that transforms complex sample collection into a streamlined, strategic advantage for clinical success.

• How AI Could Clear Logistics Roadblocks Limiting Patient Access To CGT

  Patient access often gets mischaracterized solely as a cost and pricing issue. A discussion among industry leaders reaches a deeper, more complex conclusion.

• When CGT Supply Chains Break Down: 5 Operational Gaps That Put Patient Outcomes At Risk

  Examine five of the most consequential gaps in CGT supply chain performance and learn what high-functioning teams do differently to protect patient outcomes before a failure occurs.

• Mapping Candel Therapeutics' Sprint To The BLA Finish Line

  Leaders from the adenovirus/prodrug developer discuss the complex balancing act of preparing to scale up for commercial manufacturing without overextension.